Journal Article

DKFZ-2024-02193

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.

Castro-Espin, C. ; Cairat, M. ; Navionis, A.-S. ; Dahm, C. C. ; Antoniussen, C. S. ; Tjønneland, A. ; Mellemkjær, L. ; Mancini, F. R. ; Hajji-Louati, M. ; Severi, G. ; Le Cornet, C.DKFZ* ; Kaaks, R.DKFZ* ; Schulze, M. B. ; Masala, G. ; Agnoli, C. ; Sacerdote, C. ; Crous-Bou, M. ; Sánchez, M.-J. ; Amiano, P. ; Chirlaque, M.-D. ; Guevara, M. ; Smith-Byrne, K. ; Heath, A. K. ; Christakoudi, S. ; Gunter, M. J. ; Rinaldi, S. ; Agudo, A. ; Dossus, L.

2024
Nature Publ. Group Edinburgh

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41416-024-02858-6

Abstract: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Breast Neoplasms: mortality (MeSH) ; Breast Neoplasms: blood (MeSH) ; Breast Neoplasms: diagnosis (MeSH) ; Breast Neoplasms: pathology (MeSH) ; Middle Aged (MeSH) ; Prognosis (MeSH) ; Inflammation: blood (MeSH) ; Inflammation: mortality (MeSH) ; Biomarkers, Tumor: blood (MeSH) ; Interleukin-6: blood (MeSH) ; Aged (MeSH) ; Postmenopause: blood (MeSH) ; Cohort Studies (MeSH) ; Interleukin-10: blood (MeSH) ; Adult (MeSH) ; Tumor Necrosis Factor-alpha: blood (MeSH) ; Proportional Hazards Models (MeSH) ; Biomarkers, Tumor ; Interleukin-6 ; Interleukin-10 ; Tumor Necrosis Factor-alpha ; IL6 protein, human ; IL10 protein, human

---

Contributing Institute(s):

1. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---